Asthma, rhinitis, other respiratory diseasesInhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma☆,☆☆
Section snippets
Patients
Male and nonlactating female patients 12 years of age or older with OCS-dependent asthma were recruited from existing patient populations and through advertising at each of 21 medical centers. For eligibility, patients were required to have had severe persistent asthma for at least 12 months before enrollment,20 and they were required to have needed daily or alternate-day OCSs for asthma control for 5 or more of the 6 months before enrollment. Eligible patients were also required to have an FEV1
Patient characteristics
One hundred thirty-two patients were randomized. Demographic and baseline data were similar among groups (Table I).
Empty Cell Placebo MF-DPI 400 μg BID MF-DPI 800 μg BID Demographics No. of patients 43 46* 43 Sex (M/F) 24/19 22/24 16/27 White/African American/other 37/3/3 35/8/3 39/3/1 Mean age, y (range) 55 (26-79) 49 (13-83) 53 (22-77) Body weight, lb (range) 184 (132-282) 182 (120-275) 185 (120-286) Never smoked/not in 6 mo 23/20 29/17† 30/13
Discussion
We found a clinically significant OCS-sparing effect of MF administered by means of a dry powder inhaler. Compared with patients receiving placebo whose prednisone requirements increased after randomization, those receiving either dose of MF were able to significantly reduce their prednisone requirements, and a substantial proportion discontinued its use altogether. Coincident with prednisone reduction, MF-treated patients experienced significantly better pulmonary function and symptom scores,
References (25)
- et al.
Pharmaceutically-based severity stratification of an asthmatic population
Respir Med
(1999) National Asthma Education and Prevention Program Working Group Report. Considerations for diagnosing and managing asthma in the elderly
- et al.
Unconventional approaches to drug therapy in severe asthma
Allergol Immunopathol
(1993) - et al.
Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life
Am J Respir Crit Care Med
(1995) - et al.
Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma
Chest
(1998) - et al.
Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma
J Allergy Clin Immunol
(1999) - et al.
Efficacy and safety of inhaled cortico-steroids. New developments
Am J Respir Crit Care Med
(1998) - et al.
Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis
J Allergy Clin Immunol
(1999) - et al.
Effects of budesonide by means of the Turbuhaler on the hypothalamic-pituitary-adrenal axis in asthmatic subjects: a dose-response study
J Allergy Clin Immunol
(1998) - et al.
Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent
Cutis
(1988)
Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders
Drugs
Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients
Ann Allergy Asthma Immunol
Cited by (62)
Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study
2020, The Lancet Respiratory MedicineCitation Excerpt :Mometasone furoate, indacaterol acetate, and glycopyrronium bromide have been formulated as a single, once-daily ICS–LABA–LAMA combination (MF–IND–GLY), delivered via Breezhaler, for maintenance treatment of asthma. In this dry powder formulation, indacaterol–glycopyrronium delivers once-daily bronchodilation,14,15 and mometasone offers effective once-daily anti-inflammatory therapy with excellent therapeutic index.16,17 The MF–IND–GLY combination in a single inhaler builds on the PALLADIUM18 and QUARTZ19 studies, which showed the efficacy and safety of once-daily mometasone–indacaterol (MF–IND) via Breezhaler in patients with inadequately controlled asthma.
New Insight into the Pathogenesis and Management of Refractory Childhood Asthma
2010, Pediatric Allergy: Principles and Practice Expert Consult: Second EditionAsthma in Childhood
2009, Pediatric Clinics of North AmericaCitation Excerpt :Mometasone was introduced in 1999, and evidence from a number of adult studies, some of which included adolescents, suggests a dose-dependent effect up to 400 μg/d in moderate persistent asthma, with no apparent benefit at higher doses.100,101 An OCS-sparing effect has been documented at doses of 800/1600 μg /d.102 Once-daily administration seems to be as effective as twice-daily administration at the same total daily dose. The one pediatric RCT to date in 296 children (age 4–11 years) who had mild to moderate persistent asthma showed benefit over placebo, with equal efficacy of 100 μg once-daily (evening) dosing and 100 μg twice-daily regimens.103
Zein nanoparticles as oral carrier for mometasone furoate delivery
2023, Drug Delivery and Translational ResearchIndacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A Combination Therapy for Asthma
2022, Current Respiratory Medicine ReviewsImproving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directions
2022, Expert Opinion on Drug Safety
- ☆
Supported by Schering-Plough.
- ☆☆
Reprint requests: James E. Fish, MD, Division of Pulmonary and Critical Care Medicine, Jefferson Medical College, 1025 Walnut St, Room 805, Philadelphia, PA 19107.